AKARNA THERAPEUTICS
Akarna Therapeutics is a biopharmaceutical company with offices in San Diego and Cambridge (UK) that is developing novel small molecule therapeutics that target inflammatory and fibrotic diseases. Our lead program is a non-bile acid FXR agonist that is potentially a best-in-class therapeutic for the treatment of nonalcoholic steatohepatitis (NASH), a progressive form of fatty-liver disease for which there are no approved therapies. Akarna’s lead candidate is currently in preclinical, IND-enabling toxicology and safety pharmacology studies with first-in-human studies planned for early 2017.
AKARNA THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2014-10-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.akarna.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
15 M USD
Technology used in webpage:
Domain Not Resolving Euro
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
BELX BioPharma
develop botanical new drugs for treatments of tumors, chronic liver diseases and cancers
Current Advisors List
Current Employees Featured
Founder
Investors List
Third Point Ventures
Third Point Ventures investment in Series B - Akarna Therapeutics
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Akarna Therapeutics
New Science Ventures
New Science Ventures investment in Series B - Akarna Therapeutics
